KARPAS 1718

08072401, human spleen (lymphoma), Single round to polymorphic cells growing in suspension

• UNSPSC-Code: 41106514

Eigenschaften

• product name: KARPAS 1718, 08072401
• Biologische Quelle: human spleen (lymphoma)
• Wachstumsmodus: Suspension
• Karyotyp: Not specified
• Morphologie: Single round to polymorphic cells growing in suspension
• Produkte: Not specified
• Rezeptoren: Not specified
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice
• Lagertemp.: −196°C

Beschreibung

Ursprung der Zelllinie

Human splenic lymphoma

Beschreibung der Zelllinie

KARPAS 1718 is derived from the peripheral blood of a patient diagnosed with transformed splenic lymphoma with villous lymphocytes

Anwendung

Oncology research

DNA-Profil

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 11,13
D13S317: 8,13
D16S539: 11,13
D5S818: 11,12
D7S820: 8
THO1: 6
TPOX: 8,11
vWA: 14

Nährmedium

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Subkultur-Routine

Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37°C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 105 cells/ml, 5% CO₂, 37°c. For cryopreservation of KARPAS 1718, freeze at approximately 2 x 107 cells/ml in 90% FBS + 10% DMSO.

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Haftungsausschluss

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.